These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 28012950)

  • 1. A "dose" effect of mutations in the GBA gene on Parkinson's disease phenotype.
    Thaler A; Gurevich T; Bar Shira A; Gana Weisz M; Ash E; Shiner T; Orr-Urtreger A; Giladi N; Mirelman A
    Parkinsonism Relat Disord; 2017 Mar; 36():47-51. PubMed ID: 28012950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene.
    Thaler A; Bregman N; Gurevich T; Shiner T; Dror Y; Zmira O; Gan-Or Z; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A
    Parkinsonism Relat Disord; 2018 Oct; 55():45-49. PubMed ID: 29784561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes.
    Alcalay RN; Dinur T; Quinn T; Sakanaka K; Levy O; Waters C; Fahn S; Dorovski T; Chung WK; Pauciulo M; Nichols W; Rana HQ; Balwani M; Bier L; Elstein D; Zimran A
    JAMA Neurol; 2014 Jun; 71(6):752-7. PubMed ID: 24756352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Features of
    Malek N; Weil RS; Bresner C; Lawton MA; Grosset KA; Tan M; Bajaj N; Barker RA; Burn DJ; Foltynie T; Hardy J; Wood NW; Ben-Shlomo Y; Williams NW; Grosset DG; Morris HR;
    J Neurol Neurosurg Psychiatry; 2018 Jul; 89(7):702-709. PubMed ID: 29378790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.
    Beavan M; McNeill A; Proukakis C; Hughes DA; Mehta A; Schapira AH
    JAMA Neurol; 2015 Feb; 72(2):201-8. PubMed ID: 25506732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.
    Neumann J; Bras J; Deas E; O'Sullivan SS; Parkkinen L; Lachmann RH; Li A; Holton J; Guerreiro R; Paudel R; Segarane B; Singleton A; Lees A; Hardy J; Houlden H; Revesz T; Wood NW
    Brain; 2009 Jul; 132(Pt 7):1783-94. PubMed ID: 19286695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical features of Parkinson's disease in patients with mutations and polymorphic variants of GBA gene].
    Senkevich KA; Miliukhina IV; Beletskaia MV; Gracheva EV; Kudrevatykh AV; Nikolaev MA; Emelyanov AK; Kopytova AE; Timofeeva AA; Yakimovskii AF; Pchelina SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):81-86. PubMed ID: 29171494
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Riboldi GM; Di Fonzo AB
    Cells; 2019 Apr; 8(4):. PubMed ID: 31010158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease.
    Lesage S; Anheim M; Condroyer C; Pollak P; Durif F; Dupuits C; Viallet F; Lohmann E; Corvol JC; Honoré A; Rivaud S; Vidailhet M; Dürr A; Brice A;
    Hum Mol Genet; 2011 Jan; 20(1):202-10. PubMed ID: 20947659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trio approach reveals higher risk of PD in carriers of severe vs. mild GBA mutations.
    Arkadir D; Dinur T; Mullin S; Mehta A; Baris HN; Alcalay RN; Zimran A
    Blood Cells Mol Dis; 2018 Feb; 68():115-116. PubMed ID: 27864021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
    Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
    Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease.
    Moraitou M; Hadjigeorgiou G; Monopolis I; Dardiotis E; Bozi M; Vassilatis D; Vilageliu L; Grinberg D; Xiromerisiou G; Stefanis L; Michelakakis H
    Mol Genet Metab; 2011; 104(1-2):149-52. PubMed ID: 21745757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.
    Liu G; Boot B; Locascio JJ; Jansen IE; Winder-Rhodes S; Eberly S; Elbaz A; Brice A; Ravina B; van Hilten JJ; Cormier-Dequaire F; Corvol JC; Barker RA; Heutink P; Marinus J; Williams-Gray CH; Scherzer CR;
    Ann Neurol; 2016 Nov; 80(5):674-685. PubMed ID: 27717005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcranial sonography in patients with Parkinson's disease with glucocerebrosidase mutations.
    Kresojević N; Mijajlović M; Perić S; Pavlović A; Svetel M; Janković M; Dobričić V; Novaković I; Lakočević MB; Klein C; Kostić VS
    Parkinsonism Relat Disord; 2013 Apr; 19(4):431-5. PubMed ID: 23332636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of prodromal parkinsonian features in a cohort of
    Avenali M; Toffoli M; Mullin S; McNeil A; Hughes DA; Mehta A; Blandini F; Schapira AHV
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1091-1097. PubMed ID: 31221723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort.
    Crosiers D; Verstraeten A; Wauters E; Engelborghs S; Peeters K; Mattheijssens M; De Deyn PP; Theuns J; Van Broeckhoven C; Cras P
    Neurosci Lett; 2016 Aug; 629():160-164. PubMed ID: 27397011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prodromal substantia nigra sonography undermines suggested association between substrate accumulation and the risk for GBA-related Parkinson's disease.
    Arkadir D; Dinur T; Becker Cohen M; Revel-Vilk S; Tiomkin M; Brüggemann N; Cozma C; Rolfs A; Zimran A
    Eur J Neurol; 2019 Jul; 26(7):1013-1018. PubMed ID: 30714262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?
    Goldstein O; Gana-Weisz M; Cohen-Avinoam D; Shiner T; Thaler A; Cedarbaum JM; John S; Lalioti M; Gurevich T; Bar-Shira A; Mirelman A; Giladi N; Orr-Urtreger A
    Mol Genet Metab; 2019 Dec; 128(4):470-475. PubMed ID: 31662221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.